BWX Technologies

BWXT
· NYSE
Analyzed 2026-08-099 days sinceGenerated by FomoLog Agent
FOMO Score
+0.97%
+$1.64 · per share
Report-date close → Current (2026-08-17)
$169.90$171.54
Days Held
9d
Price As Of
2026-08-17
Not investment adviceThis is not investment advice. FomoLog provides factual summaries and post-hoc price-change context only. Investment decisions and their outcomes are solely the responsibility of the investor.Legal Notice ↗

Price Trend

Report date → now · daily close
$168$170$172$174Aug 10Aug 12Aug 13Aug 17Report date $169.90Current $171.54

Summary

BWX Technologies reported Q2 2026 (announced 2026-08-03) revenue of 901.6 million USD (+18% YoY) and GAAP diluted EPS of 0.97 USD, with Government Operations accounting for 66.7% of revenue and Commercial Operations 33.6%. The same day, the company raised its full-year 2026 revenue outlook to approximately 3.80 billion USD and signed an agreement to divest more than an 80% stake in its medical and stable isotopes businesses to Nordic Capital for up to 800 million USD. As of Q2 2026, the backlog stood at 8.4 billion USD, up 40% year-over-year. The closing price was 169.9 USD as of 2026-08-07, up +1.92% from the prior day (166.7 USD).

Price-Change Context Note

On 2026-08-03, the day of the earnings announcement, the stock rose +3.02% during regular trading but fell -3.23% in after-hours trading, reportedly reflecting revenue slightly missing consensus (905.4 million USD) and a downward revision of the Commercial Operations adjusted EBITDA margin outlook from approximately 14% to approximately 13% (Investing.com, 2026-08-03). Total liabilities at year-end 2025 increased 69.8% year-over-year, a period that included acquisitions such as Precision Components Group and Kinectrics.

Key Facts

Q2 2026 revenue of 901.6 million USD (+18% YoY), GAAP diluted EPS of 0.97 USD (+14% YoY) — BusinessWire, 2026-08-03
Raised full-year 2026 guidance: revenue approximately 3.80 billion USD, adjusted EPS 4.70–4.80 USD — company announcement, 2026-08-03
Backlog of 8.4 billion USD (+40% YoY); trailing-12-month book-to-bill ratio of 1.7x — Q2 2026 earnings release
Total liabilities at year-end 2025 rose +69.8% year-over-year (from 1,789.52 million USD to 3,038.48 million USD), with a debt ratio of 246.5% — audited financial data
BlackRock holds 10.3% and Vanguard holds 10.1%; board independence ratio of 90% (9 of 10 members) — DEF 14A, 2026-03-18
Signed agreement on 2026-08-03 to divest medical business for up to 800 million USD; completed acquisition of Precision Components Group on 2026-07-06

Theme Relevance

#M&A
3/5
#Defense & Security
5/5
#Nuclear Power
5/5
#Power Infrastructure
3/5
#US Reshoring
3/5

Full Analysis

BWX Technologies (BWXT · NYSE)
Analysis date 2026-08-09 · Reference close 169.9 USD (2026-08-07) · vs. prior day +1.92% · Volume 674,936 shares
Market cap 15.57 billion USD (91,621,980 shares outstanding, as of 2026-07-31) · Provided under the Capital Markets Act as factual summaries, FOMO metrics, and theme relevance only — not investment advice

Factual Summary

BWX Technologies reported Q2 2026 (announced 2026-08-03) revenue of 901.6 million USD (+18% YoY) and GAAP diluted EPS of 0.97 USD, with Government Operations accounting for 66.7% of revenue and Commercial Operations 33.6%. The same day, the company raised its full-year 2026 revenue outlook to approximately 3.80 billion USD and signed an agreement to divest more than an 80% stake in its medical and stable isotopes businesses to Nordic Capital for up to 800 million USD. As of Q2 2026, the backlog stood at 8.4 billion USD, up 40% year-over-year.

Price-Change Context Note

On 2026-08-03, the day of the earnings announcement, the stock rose +3.02% during regular trading but fell -3.23% in after-hours trading, reportedly reflecting revenue slightly missing consensus (905.4 million USD) and a downward revision of the Commercial Operations adjusted EBITDA margin outlook from approximately 14% to approximately 13% (Investing.com, 2026-08-03). Total liabilities at year-end 2025 increased 69.8% year-over-year, a period that included acquisitions such as Precision Components Group and Kinectrics.

Business Composition

BWXT operates in two business segments. Government Operations manufactures reactors and related nuclear fuel for the U.S. Navy's nuclear propulsion program (submarines and aircraft carriers), while Commercial Operations produces steam generators, fuel, fuel-handling systems, and pressure vessels for commercial reactors (stockanalysis.com Company Profile, accessed 2026-08-09). In Q2 2026, Government Operations revenue was 601.3 million USD (+2% YoY) and Commercial Operations revenue was 302.5 million USD (+72% YoY), with Commercial Operations showing strong organic growth.

Government Operations
66.7%
Commercial Operations
33.6%
As of Q2 2026 (announced 2026-08-03) · Source: BusinessWire (A)

5-Year Revenue Trend (Based on Annual Reports)

Annual Revenue (Unit: billion USD)
2.122.232.502.703.2020212022202320242025
As of each annual report (10-K) fiscal year-end · Source: SEC EDGAR audited financial data (A)
PeriodRevenue (million USD)Operating Income (million USD)Net Income (million USD)Operating Margin
20212,12434630616.3%
20222,23334923815.6%
20232,49638324615.3%
20242,70438128214.1%
20253,19840432912.6%

Revenue CAGR (2021→2025) approximately +10.8%/year. Operating margin gradually declined from 16.3% in 2021 to 12.6% in 2025 (calculated based on audited financial data, A).

Valuation (Factual Multiples)

PER (TTM, GAAP)
43.83x
Closing price 2026-08-07 · Financials as of 2026-06-30 (A)
PBR
11.67x
Total equity as of 2026-06-30 (A)
Market Cap
15.57 billion USD
91,621,980 shares outstanding, 2026-07-31 (A)
TTM EPS
3.88 USD
Sum of 2025-07 to 2026-06 (A)

Based on web-aggregated figures (non-GAAP, differing methodology), trailing PER is also reported at 47.90x and EV/EBITDA at 38.17x (stockanalysis.com, accessed 2026-08). Because cash-and-equivalents figures needed to calculate net debt were not available in audited data, EV/EBITDA was not independently calculated (not available).

Peer Comparison

BWXT is classified as one of a small number of companies in North America that produce specialized nuclear components, nuclear fuel systems, and naval reactor systems at scale (Motley Fool, accessed 2026-08-09). Key peers for comparison are Curtiss-Wright (CW, which supplies reactor components across three segments including Naval & Power) and small modular reactor designer NuScale Power (SMR).

Trailing PER Comparison
43.83x51.4xBWXTCurtiss-Wright
BWXT calculated in-house based on 2026-08-07 closing price and 2026-06-30 financials (A); Curtiss-Wright as of 2026-06-30, web-aggregated (E) · Source: this report's calculations + gurufocus.com/fullratio.com
ItemBWXTCurtiss-WrightNuScale Power
2025 Revenue3.198 billion USD (A)approximately 3.50 billion USD (E)approximately 31.48 million USD (E)
2025 Net Income329 million USD (A)approximately 484 million USD (E)approximately -356 million USD (E)
Government Customer Revenue Shareapproximately 66.7% (A, Q2 2026)approximately 58% (E, 2025)Not available
Backlog8.4 billion USD (A, +40% YoY)approximately 4.1 billion USD (E, 2025)Not applicable

Capital Structure & Financial Health

Total Liabilities, End of 2024
1.79 billion USD
Debt ratio 165.6% (A)
Total Liabilities, End of 2025
3.038 billion USD
Debt ratio 246.5%, +69.8% YoY (A)
Total Liabilities, Mid-2026
3.089 billion USD
Debt ratio 231.5% (A)

On 2025-11-10, the company issued 1.25 billion USD (up to 1.4 billion USD including the option) of 0% convertible preferred notes due 2030 and entered into a 1.25 billion USD revolving credit facility, coinciding with acquisitions including Precision Components Group and Kinectrics (SEC 8-K, cross-checked with financials.md and news.md). The U.S. 10-year Treasury yield was approximately 4.65–4.68% as of 2026-08-07, with a 61.9% probability of a rate hike at the September FOMC meeting (as of 2026-08-04) cited as a headwind for new and refinancing funding costs (macro.md).

Governance

BlackRock, Inc.
10.3%
The Vanguard Group
10.1%
William Blair Investment Mgmt
3.5%
Wellington Management Group
3.25%
Ownership percentages as of 2026-03-06 (DEF 14A) · William Blair and Wellington as of 2024-09-30 (SC 13G/A) · Source: SEC EDGAR (A)
Board Size
10 members
Expanded effective 2026-03-02 (DEF 14A)
Independent Director Ratio
90%
9 independent, 1 internal (CEO); Chair and CEO roles separated
DateEvent
2025-11-10Issued 1.25 billion USD of 0% convertible preferred notes due 2030 and entered into a new 1.25 billion USD revolving credit facility
2026-02-20Board expanded from 9 to 10 members; Daniel L. Jablonsky appointed as new outside director
2026-04-30Annual shareholders meeting; all 10 directors re-elected
2026-07-06Completed acquisition of Precision Components Group
2026-08-03Signed agreement to divest medical and stable isotopes businesses (Nordic Capital, up to 800 million USD)

BWXT was spun off from Babcock & Wilcox Company in 2015 and has no individual controlling shareholder; only BlackRock and Vanguard have reported holdings of 5% or more (DEF 14A, as of 2026-03-18).

Supply-Demand Trends

Short Interest (% of Float)
3.29%
stockanalysis.com, accessed 2026-08-09 (E)
Institutional Ownership
93–94%
Varies by source (93.11–94.39%) (E)
20-Day Average Volume
966,161 shares
stockanalysis.com, 2026-08-09 (E)

In May 2026, share dispositions by CEO Rex D. Geveden (10,000 common shares) and CFO Michael Thomas Fitzgerald (2,417 common shares) were disclosed as routine sales under a 10b5-1 pre-arranged plan adopted on 2025-08-11 (SEC Form 4, StockTitan). 10b5-1 pre-arranged plan Short interest is reported in a range of 2.75–3.29% depending on the source, and is confirmed to be similar to or slightly below the industry average (3.59%, per Sahm Capital).

Macro Linkages

FactorCurrent ValueTransmission Path to BWXT
U.S. Navy FY2027 Shipbuilding Budget65.8 billion USD (+23% YoY)Expanded construction volume for Virginia- and Columbia-class submarines and Ford-class carriers → increased orders for naval reactor components and nuclear fuel
DOE SMR & Nuclear Expansion Policy8 companies selected for SMR program on 2026-05-14; 21.4 million USD awarded to BWXTExpanded support policy for next-generation reactors → growth in Commercial Operations orders and backlog
Data Center-Driven Power DemandBacklog of 8.4 billion USD (+40% YoY)Spread of nuclear power offtake agreements by major tech companies amid growing data center power demand → contributing to commercial backlog growth
U.S. Federal Funds Rate3.50–3.75% (held steady 2026-07-29)Upward pressure on new and refinancing funding costs (limited near-term impact since existing debt is fixed-rate)
As of 2026-08-09 · Source: compiled from GT Law, DOE, CNN Business, macro.md (mix of A/E)

Recent Event Timeline

DateEvent
2026-07-06Completed acquisition of Precision Components Group (expanding U.S. manufacturing capacity)
2026-07-31Board declared quarterly cash dividend of 0.27 USD per share (payment date 2026-09-04)
2026-08-03Announced Q2 2026 results (revenue 901.6 million USD, EPS 0.97 USD) and raised full-year outlook
2026-08-03Signed agreement to divest medical and stable isotopes businesses (Nordic Capital, up to 800 million USD)

Fact-Based Risk Factors

  • A significant portion of revenue (Government Operations accounted for 66.7% as of Q2 2026) depends on U.S. government contracts and is subject to congressional budget appropriations (compiled from 10-K disclosures).
  • At the 2026-08-03 earnings announcement, the Commercial Operations adjusted EBITDA margin outlook was revised down from approximately 14% to approximately 13% (reflecting the impact of upfront investment in capacity expansion and hiring).
  • The debt ratio rose sharply to 246.5% at the end of 2025 from 165.6% a year earlier, and remained elevated at 231.5% at mid-2026.
  • The stock is trading at trailing PER of 43.83x (A) to 47.90x (E) and EV/EBITDA of approximately 38x, multiples that are elevated relative to historical averages.
  • Given the nature of the business, risks to human life, property, and the environment are ever-present, and the company is subject to ongoing review by the EPA, NRC, and other regulators (compiled from 10-K disclosures).

Theme Relevance

Nuclear Power
5
All of Q2 2026 revenue of 901.6 million USD came from nuclear-related businesses, including naval reactor and fuel manufacturing (Government Operations, 66.7% of revenue) and commercial reactor components and fuel (Commercial Operations, 33.6% of revenue) (BusinessWire, 2026-08-03).
Defense & Security
5
The Government Operations segment won contracts totaling 1.45 billion USD related to the U.S. Navy's nuclear propulsion program on 2026-05-07, and this segment accounted for 66.7% of revenue as of Q2 2026 (BusinessWire, 2026-05-07).
Power Infrastructure
3
Q2 2026 backlog rose to 8.4 billion USD, up +40% year-over-year, with the spread of nuclear power offtake agreements by major tech companies amid growing data center power demand cited as a driver of Commercial Operations order growth (Investing.com, accessed 2026-08-09).
U.S. Manufacturing Reshoring
3
On 2026-07-06, the company completed the acquisition of Precision Components Group, adding more than 500,000 square feet of heavy manufacturing capacity in the U.S. and more than 450 employees to Commercial Operations (BWXT press release, 2026-07-06).
M&A
3
On 2026-08-03, the company signed a definitive agreement to divest more than an 80% stake in its medical business (BWXT Medical) and Kinectrics stable isotopes business to Nordic Capital for up to 800 million USD (BWXT press release, 2026-08-03).

Fact Highlights

Q2 2026 revenue of 901.6 million USD (+18% YoY), GAAP diluted EPS of 0.97 USD (+14% YoY) — BusinessWire, 2026-08-03
Raised full-year 2026 guidance: revenue approximately 3.80 billion USD, adjusted EPS 4.70–4.80 USD — company announcement, 2026-08-03
Backlog of 8.4 billion USD (+40% YoY); trailing-12-month book-to-bill ratio of 1.7x — Q2 2026 earnings release
Total liabilities at year-end 2025 rose +69.8% year-over-year (from 1,789.52 million USD to 3,038.48 million USD), with a debt ratio of 246.5% — audited financial data
BlackRock holds 10.3% and Vanguard holds 10.1%; board independence ratio of 90% (9 of 10 members) — DEF 14A, 2026-03-18
Signed agreement on 2026-08-03 to divest medical business for up to 800 million USD; completed acquisition of Precision Components Group on 2026-07-06

This is not investment advice. FomoLog provides factual summaries and post-hoc price-change context only. Investment decisions and their outcomes are solely the responsibility of the investor.

Generated by FomoLog Agent · Data sources: Korea Exchange · NASDAQ · DART · SEC EDGAR